story of the week
Association Between Treatment Intensity and Measurable Residual Disease and Outcomes in Patients With AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity
Blood Adv 2023 Mar 08;[EPub Ahead of Print], A Bazinet, TM Kadia, NJ Short, G Borthakur, SA Wang, W Wang, S Loghavi, JL Jorgensen, KP Patel, CD DiNardo, NG Daver, Y Alvarado, FG Haddad, SR Pierce, GM Nogueras Gonzalez, A Maiti, K Sasaki, M Yilmaz, PA Thompson, WG Wierda, G Garcia-Manero, M Andreeff, EJ Jabbour, MY Konopleva, X Huang, HM Kantarjian, F RavandiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.